PRKD3 and breast carcinoma: Furthermore, PKD inhibitors reduced cell growth in cells expressing higher levels of PKD3 and outperformed inhibition of PKC, suggesting that PKD3 is the main isoform driving tumor progression in breast cancer (Hao et al., 2013).